Briacell Therapeutics Corp (BCTX)

$3.64 -0.06 (-1.62%)
Market Cap 30.36M
Revenue (ttm) 0.00
Net Income (ttm) -26.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 158,000
Avg Vol 217,668
Day's Range N/A - N/A
Shares Out 8.70M
Stochastic %K 86%
Beta 1.15
Analysts Strong Buy
Price Target $40.00

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 921 1810
Fax: 604 921 1898
Address:
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada
TWBXX
TWBXX Jul. 9 at 8:44 PM
$BCTX The interim readout is now a near-term catalyst If the 144-event interim occurs between now and December 2026, then: BCTX has a major binary catalyst within months The market will begin pricing in anticipation Institutional interest increases as the event approaches 3. The staggered enrollment is actually beneficial Because early patients have long follow-up: The interim will include mature survival data The treatment effect (if positive) will be clearer The DSMC will have stronger statistical power to evaluate benefit This increases the chance of: Stopping early for efficacy Accelerating regulatory pathways Attracting partnership or acquisition interest
0 · Reply
BHWinehouse
BHWinehouse Jul. 9 at 7:34 PM
$BCTX I just went down the buyout rabbit hole. Holy shit, if we get good results this could be much bigger than I ever expected!
0 · Reply
nik4
nik4 Jul. 9 at 6:12 PM
$BCTX So the approximate enrollment timeline is: Date Milestone Oct 2023 Trial initiated / enrollment began Early 2024 (estimated) First patients likely enrolled Apr 2025 >75 patients enrolled Dec 2025 >160 patients enrolled May 2026 >230 patients enrolled For estimating the 144-event interim analysis, the important point is that the earliest patients may have had roughly 2.5–3 years of follow-up by mid/late 2026, while the newest patients may have only months of follow-up. That staggered enrollment is why the exact timing of the 144th death is difficult to predict.....nevertheless 144-event interim analysis will happen in 2026(now to December),reported by company.
0 · Reply
Biohero
Biohero Jul. 9 at 11:00 AM
$BCTX What do you think is a fair market value right now? 144th event in a final P3 study (not 1b or 2a) is gradually approaching... 50m, 100m, 150m$? I'm still adding shares...
1 · Reply
letsdodiz
letsdodiz Jul. 8 at 11:38 PM
$BCTX On the roadshow Dr Williams mentioned that Dr Sara Hurvitz nominated Briacell to the nature magazine top 11 clinical trials to watch in 2026. Dr Hurvitz is a leading oncologist researcher and has dealt with advanced stage cancer for at least 15-20 years in her career . To recommend Briacell to an esteemed journal when she constantly comes across numerous clinical stage therapies speaks volumes about its success with TNBC and other subtypes of cancer.
2 · Reply
letsdodiz
letsdodiz Jul. 8 at 11:28 PM
$BCTX bctxl warrants is the only leverage play here . SP $6.93. Expiry- 01/2031 . Current value 95c. If share price goes to $40 it will be around $30-32 which is approximately 30-35x. Risky but more bang for buck on a binary event. Not asking anyone to buy.. play at your own risk.
3 · Reply
StormHunter89
StormHunter89 Jul. 8 at 7:37 PM
$BCTX 5k shares for me 🐒❤️ now moon🚀
3 · Reply
Biohero
Biohero Jul. 8 at 4:35 PM
$BCTX keep on adding shares, we are still under the radar
0 · Reply
jfun1
jfun1 Jul. 8 at 4:24 PM
$BCTX nice and steady
0 · Reply
Manwiththeplan
Manwiththeplan Jul. 8 at 4:08 PM
$BCTX
0 · Reply
Latest News on BCTX
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

Tue, 07 Jul 2026 07:30:00 -0400 - 2 days ago

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

BriaCell Partners With Uneedle To Support Scalable Microneedle Delivery Of Bria-IMT

2026-06-26T10:06:07.000Z - 13 days ago

BriaCell Partners With Uneedle To Support Scalable Microneedle Delivery Of Bria-IMT

BriaCell (BCTX) Partners with Uneedle for Microneedle Technology Development

2026-06-25T13:25:58.000Z - 14 days ago

BriaCell (BCTX) Partners with Uneedle for Microneedle Technology Development

BriaCell enters MoU with Uneedle for microneedle technology

2026-06-25T11:45:30.000Z - 14 days ago

BriaCell enters MoU with Uneedle for microneedle technology

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™

Thu, 25 Jun 2026 07:30:00 -0400 - 14 days ago

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™

BriaCell Therapeutics Announces Closing of Offering

Tue, 02 Jun 2026 16:05:00 -0400 - 5 weeks ago

BriaCell Therapeutics Announces Closing of Offering

BriaCell Presents Positive Clinical Data at ASCO 2026

Mon, 01 Jun 2026 07:30:00 -0400 - 5 weeks ago

BriaCell Presents Positive Clinical Data at ASCO 2026

BriaCell Therapeutics Announces Pricing of Offering

Sun, 31 May 2026 19:59:00 -0400 - 5 weeks ago

BriaCell Therapeutics Announces Pricing of Offering

BriaCell (BCTX) Receives Positive Update from Data Safety Monitoring Board

2026-05-26T14:43:01.000Z - 6 weeks ago

BriaCell (BCTX) Receives Positive Update from Data Safety Monitoring Board

BriaCell receives recommendation for DSMB for Phase 3 Bria-ABC study

2026-05-26T13:05:39.000Z - 6 weeks ago

BriaCell receives recommendation for DSMB for Phase 3 Bria-ABC study

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Tue, 26 May 2026 07:30:00 -0400 - 6 weeks ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026

2026-05-22T13:27:19.000Z - 6 weeks ago

BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026

BriaCell announces data from Bria-IMT at ASCO 2026

2026-05-22T11:49:02.000Z - 6 weeks ago

BriaCell announces data from Bria-IMT at ASCO 2026

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

Fri, 22 May 2026 07:30:00 -0400 - 6 weeks ago

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

Fri, 15 May 2026 07:30:00 -0400 - 7 weeks ago

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment

2026-05-14T15:31:53.000Z - 2 months ago

BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

Thu, 14 May 2026 07:30:00 -0400 - 2 months ago

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment

2026-05-13T16:39:28.000Z - 2 months ago

BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment

BriaCell adds Penn Medicine as Phase 3 breast cancer study site

2026-05-13T14:41:55.000Z - 2 months ago

BriaCell adds Penn Medicine as Phase 3 breast cancer study site

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Wed, 13 May 2026 07:30:00 -0400 - 2 months ago

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

Tue, 12 May 2026 07:30:00 -0400 - 2 months ago

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Thu, 07 May 2026 07:30:00 -0400 - 2 months ago

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

BriaCell receives FDA clearance to initiate Bria-BRES+ trial

2026-05-07T04:03:56.000Z - 2 months ago

BriaCell receives FDA clearance to initiate Bria-BRES+ trial

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

Wed, 06 May 2026 07:30:00 -0400 - 2 months ago

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

Mon, 27 Apr 2026 07:30:00 -0400 - 2 months ago

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

2026-04-21T13:28:43.000Z - 2 months ago

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

BriaCell presents anti-cancer activity of Bria-OTS

2026-04-21T11:54:23.000Z - 2 months ago

BriaCell presents anti-cancer activity of Bria-OTS

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

Tue, 21 Apr 2026 07:30:00 -0400 - 2 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

2026-04-20T13:32:04.000Z - 2 months ago

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR

2026-04-20T11:41:56.000Z - 2 months ago

BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

Mon, 20 Apr 2026 07:30:00 -0400 - 2 months ago

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

Tue, 31 Mar 2026 16:05:00 -0400 - 3 months ago

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

2026-03-18T13:30:56.000Z - 4 months ago

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

BriaCell to present four posters at the 2026 AACR

2026-03-18T11:42:55.000Z - 4 months ago

BriaCell to present four posters at the 2026 AACR

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

Wed, 18 Mar 2026 07:30:00 -0400 - 4 months ago

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

Tue, 10 Mar 2026 07:30:00 -0400 - 4 months ago

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

Thu, 05 Mar 2026 16:04:00 -0500 - 4 months ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

2026-02-18T22:51:30.000Z - 5 months ago

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

BriaPro to purchase BriaCell’s license to develop, commercialize sCD80

2026-02-18T22:35:25.000Z - 5 months ago

BriaPro to purchase BriaCell’s license to develop, commercialize sCD80

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

Wed, 18 Feb 2026 17:30:00 -0500 - 5 months ago

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

BriaCell receives positive recommendation from DSMB for Phase 3 Bria-ABC study

2026-02-17T12:40:59.000Z - 5 months ago

BriaCell receives positive recommendation from DSMB for Phase 3 Bria-ABC study

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Tue, 17 Feb 2026 07:30:00 -0500 - 5 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment

2026-01-28T13:30:56.000Z - 5 months ago

BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment

BriaCell says patient images show regression, resolution of metastsized tumors

2026-01-28T12:40:40.000Z - 5 months ago

BriaCell says patient images show regression, resolution of metastsized tumors

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

Wed, 28 Jan 2026 07:30:00 -0500 - 5 months ago

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

BriaCell (BCTX) Reports Promising Phase 2 Survival Data

2026-01-27T13:32:37.000Z - 5 months ago

BriaCell (BCTX) Reports Promising Phase 2 Survival Data

BriaCell extends 18-47 month survival in Phase 2 metastatic breast cancer

2026-01-27T12:41:04.000Z - 5 months ago

BriaCell extends 18-47 month survival in Phase 2 metastatic breast cancer

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

Tue, 27 Jan 2026 07:30:00 -0500 - 5 months ago

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?

2026-01-19T16:00:45.000Z - 6 months ago

Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?

Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch

2026-01-16T13:58:57.000Z - 6 months ago

Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

Jan 15, 2026, 4:05 PM EST - 6 months ago

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

Jan 13, 2026, 9:00 PM EST - 6 months ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

BriaCell Therapeutics trading resumes

2026-01-13T14:41:11.000Z - 6 months ago

BriaCell Therapeutics trading resumes

BriaCell Therapeutics trading halted, volatility trading pause

2026-01-13T14:35:29.000Z - 6 months ago

BriaCell Therapeutics trading halted, volatility trading pause

BriaCell reports sustained complete resolution of lung metastasis in Bria-OTS

2026-01-13T12:35:49.000Z - 6 months ago

BriaCell reports sustained complete resolution of lung metastasis in Bria-OTS

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

Jan 13, 2026, 7:30 AM EST - 6 months ago

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

Dec 18, 2025, 7:30 AM EST - 7 months ago

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

BriaCell presents Phase 2, Phase 3 data on Bria-IMT at SABCS 2025

2025-12-10T12:41:29.000Z - 7 months ago

BriaCell presents Phase 2, Phase 3 data on Bria-IMT at SABCS 2025

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

Dec 10, 2025, 7:30 AM EST - 7 months ago

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

BriaCell announces Phase 3 patient enrollment on track for 1H26 data readout

2025-12-09T12:35:35.000Z - 7 months ago

BriaCell announces Phase 3 patient enrollment on track for 1H26 data readout

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

Dec 9, 2025, 7:30 AM EST - 7 months ago

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

BriaCell to present Phase 2 survival, Phase 3 data at SABCS 2025

2025-12-02T12:36:29.000Z - 7 months ago

BriaCell to present Phase 2 survival, Phase 3 data at SABCS 2025

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Dec 2, 2025, 7:30 AM EST - 7 months ago

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

Nov 25, 2025, 7:30 AM EST - 8 months ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Nov 20, 2025, 7:30 AM EST - 8 months ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Nov 18, 2025, 7:30 AM EST - 8 months ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Nov 7, 2025, 7:30 AM EST - 8 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

Nov 4, 2025, 7:30 AM EST - 8 months ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Oct 21, 2025, 7:50 AM EDT - 9 months ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Oct 21, 2025, 7:30 AM EDT - 9 months ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Oct 20, 2025, 7:30 AM EDT - 9 months ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 13, 2025, 7:30 AM EDT - 9 months ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Oct 3, 2025, 7:30 AM EDT - 9 months ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 26, 2025, 7:30 AM EDT - 11 months ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 25, 2025, 7:30 AM EDT - 11 months ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 21, 2025, 12:00 PM EDT - 11 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Aug 13, 2025, 7:30 AM EDT - 11 months ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 31, 2025, 7:30 AM EDT - 1 year ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

Jul 30, 2025, 7:30 AM EDT - 1 year ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

Jul 29, 2025, 7:30 AM EDT - 1 year ago

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Jul 25, 2025, 7:30 AM EDT - 1 year ago

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

BriaCell Therapeutics Announces Closing of $15 million Public Offering

Jul 16, 2025, 4:05 PM EDT - 1 year ago

BriaCell Therapeutics Announces Closing of $15 million Public Offering

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

Jul 15, 2025, 3:05 PM EDT - 1 year ago

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

TWBXX
TWBXX Jul. 9 at 8:44 PM
$BCTX The interim readout is now a near-term catalyst If the 144-event interim occurs between now and December 2026, then: BCTX has a major binary catalyst within months The market will begin pricing in anticipation Institutional interest increases as the event approaches 3. The staggered enrollment is actually beneficial Because early patients have long follow-up: The interim will include mature survival data The treatment effect (if positive) will be clearer The DSMC will have stronger statistical power to evaluate benefit This increases the chance of: Stopping early for efficacy Accelerating regulatory pathways Attracting partnership or acquisition interest
0 · Reply
BHWinehouse
BHWinehouse Jul. 9 at 7:34 PM
$BCTX I just went down the buyout rabbit hole. Holy shit, if we get good results this could be much bigger than I ever expected!
0 · Reply
nik4
nik4 Jul. 9 at 6:12 PM
$BCTX So the approximate enrollment timeline is: Date Milestone Oct 2023 Trial initiated / enrollment began Early 2024 (estimated) First patients likely enrolled Apr 2025 >75 patients enrolled Dec 2025 >160 patients enrolled May 2026 >230 patients enrolled For estimating the 144-event interim analysis, the important point is that the earliest patients may have had roughly 2.5–3 years of follow-up by mid/late 2026, while the newest patients may have only months of follow-up. That staggered enrollment is why the exact timing of the 144th death is difficult to predict.....nevertheless 144-event interim analysis will happen in 2026(now to December),reported by company.
0 · Reply
Biohero
Biohero Jul. 9 at 11:00 AM
$BCTX What do you think is a fair market value right now? 144th event in a final P3 study (not 1b or 2a) is gradually approaching... 50m, 100m, 150m$? I'm still adding shares...
1 · Reply
letsdodiz
letsdodiz Jul. 8 at 11:38 PM
$BCTX On the roadshow Dr Williams mentioned that Dr Sara Hurvitz nominated Briacell to the nature magazine top 11 clinical trials to watch in 2026. Dr Hurvitz is a leading oncologist researcher and has dealt with advanced stage cancer for at least 15-20 years in her career . To recommend Briacell to an esteemed journal when she constantly comes across numerous clinical stage therapies speaks volumes about its success with TNBC and other subtypes of cancer.
2 · Reply
letsdodiz
letsdodiz Jul. 8 at 11:28 PM
$BCTX bctxl warrants is the only leverage play here . SP $6.93. Expiry- 01/2031 . Current value 95c. If share price goes to $40 it will be around $30-32 which is approximately 30-35x. Risky but more bang for buck on a binary event. Not asking anyone to buy.. play at your own risk.
3 · Reply
StormHunter89
StormHunter89 Jul. 8 at 7:37 PM
$BCTX 5k shares for me 🐒❤️ now moon🚀
3 · Reply
Biohero
Biohero Jul. 8 at 4:35 PM
$BCTX keep on adding shares, we are still under the radar
0 · Reply
jfun1
jfun1 Jul. 8 at 4:24 PM
$BCTX nice and steady
0 · Reply
Manwiththeplan
Manwiththeplan Jul. 8 at 4:08 PM
$BCTX
0 · Reply
CAN29
CAN29 Jul. 8 at 3:46 PM
$BCTX Everything down today - BCTX up 7% 🤔
0 · Reply
Fvalstounge
Fvalstounge Jul. 8 at 3:45 PM
$BCTX Looks like time for another round of Bingo.
1 · Reply
Manwiththeplan
Manwiththeplan Jul. 8 at 2:54 PM
$BCTX the later the data, the better the news
0 · Reply
Manwiththeplan
Manwiththeplan Jul. 8 at 2:41 PM
$BCTX
0 · Reply
Forestbird
Forestbird Jul. 8 at 11:10 AM
$BCTX How do you see dilutation risk?
3 · Reply
StormHunter89
StormHunter89 Jul. 8 at 4:52 AM
$BCTX It's interesting that not much people have this on their watch list. With a float of 8-12m shares, any good news will fire the stock price into the atmosphere. It dropped more than 80% in a year. Watch it to go to 40x the price it has now as soon as the 144th event drops. It's like investing in $SLS but at 0,15$
5 · Reply
Ares77manoe
Ares77manoe Jul. 7 at 7:53 PM
$BCTX funny to see clowns showing up with their science just after PR...lol
0 · Reply
Merlintrader
Merlintrader Jul. 7 at 7:38 PM
$BCTX
0 · Reply
Orlandotrader
Orlandotrader Jul. 7 at 6:53 PM
$BCTX Lots of Positioning and Market Still a non believer. I like that a lot. Seems to be more Believers here lately. Nice Not talking a Large position here but will Trade this as they Prove Themselves.
0 · Reply
ZacksResearch
ZacksResearch Jul. 7 at 6:21 PM
$BCTX is already preparing for a potential commercial launch — and Bria-IMT is still in Phase 3 👀 BriaCell just engaged $CRAI and Kaleio to support commercial strategy, market access evaluation, and brand planning for Bria-IMT as its pivotal Phase 3 metastatic breast cancer study continues. ⚕️ The company says this is a commercial-readiness step tied to potential future commercialization planning, pending successful clinical development and regulatory approvals. See what Wall Street expects next 👉 https://www.zacks.com/stock/research/BCTX/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-38679&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_38679
0 · Reply
Merlintrader
Merlintrader Jul. 7 at 5:06 PM
$BCTX BriaCell Therapeutics ($BCTX) Stock Hub: Bria-IMT Phase 3, ASCO 2026, Commercial Readiness and Dilution Risk https://www.merlintrader.com/briacell-therapeutics-stock-hub/
0 · Reply
SmallCapGrowth
SmallCapGrowth Jul. 7 at 4:43 PM
$BCTX BriaCell continues positioning Bria-IMT™ for potential future commercialization, subject to clinical and regulatory success. NEWS: https://bit.ly/3QK1eTD #BiotechNews #HealthcareStocks #Oncology
0 · Reply